ijms-logo

Journal Browser

Journal Browser

55th Anniversary of IgE Discovery: Pros and Cons of Anti-IgE Treatment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1238

Special Issue Editors


E-Mail Website
Guest Editor
Allergy and Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Messina, 98214 Messina, Italy
Interests: allergy and clinical immunology; lung; asthma
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy
Interests: inflammatory mediators; the citokine network (interleukins, chemokines, adhesion molecules, lipoxines); the oxidative stress in various areas of clinical immunology; allergy; oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

IgE is the fifth class of immunoglobulins, discovered in 1967 by Kimishige and Teruko Ishizaka, a married couple of exceptional scientists. Their laboratory findings led to the discovery of IgE, an important step in the process of starting to unravel the mechanisms underlying allergic reactions.

After this discovery, the field of allergy diagnosis and treatment gained increasing interest from scientists, physicians, and the general population.

The industrialization process, which started in the post-World War era, increased this process as higher rates of sensitization were found.

Nowadays, IgE is well known to be elicited by allergens and to be involved in the protection of hosts from helminth infestation. Their function is carried out through interactions with specific receptors and activation mechanisms.

The discovery of anti-IgE treatments such as omalizumab represented a milestone in the treatment of diseases such as severe allergic asthma and chronic spontaneous urticaria, even if the full potential of this drug has yet to be exploited.

This IJMS Special Issue aims to collect a series of articles, either original or reviews, in order to better define the role of anti-IgE treatment.

Prof. Dr. Luisa Ricciardi
Prof. Dr. Sebastiano Gangemi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • IgE
  • anti-IgE
  • omalizumab
  • precision medicine
  • allergens
 

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1372 KiB  
Review
The Incredible Adventure of Omalizumab
by Christian Domingo, Daniel R. Monserrate, Ana Sogo and Rosa M. Mirapeix
Int. J. Mol. Sci. 2024, 25(5), 3056; https://doi.org/10.3390/ijms25053056 - 6 Mar 2024
Viewed by 902
Abstract
The basis of our current understanding of allergies begins with the discovery of IgE in the mid-1960s. The whole theory of the physiology and pathophysiology of allergic diseases, including rhinitis and asthma, dates from that period. Among the key regions of IgE identified [...] Read more.
The basis of our current understanding of allergies begins with the discovery of IgE in the mid-1960s. The whole theory of the physiology and pathophysiology of allergic diseases, including rhinitis and asthma, dates from that period. Among the key regions of IgE identified were the FAB (fragment antigen binding) portion that has the ability to capture allergens, and the Cε3 domain, through which IgE binds to its membrane receptor. It was then postulated that blocking IgE at the level of the Cε3 domain would prevent it from binding to its receptor and thus set in motion the allergic cascade. This was the beginning of the development of omalizumab, a monoclonal antibody with an anti-IgE effect. In this article, we review the pathophysiology of allergic disease and trace the clinical development of omalizumab. We also review the benefits of omalizumab treatment that are apparently unrelated to allergies, such as its effect on immunity and bronchial remodeling. Full article
Show Figures

Figure 1

Back to TopTop